- Home
- TOVX vs APRE Comparison
TOVX vs APRE Comparison
Compare TOVX & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TOVX | APRE |
|---|---|---|
| Founded | 2001 | 2006 |
| Country | United States | United States |
| Employees | N/A | 8 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4M | 8.4M |
| IPO Year | 2012 | 2019 |
Fundamental Metrics
Financial Performance| Metric | TOVX | APRE |
|---|---|---|
| Price | $0.17 | $0.72 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | ★ 5.8M | 231.3K |
| Earning Date | 06-19-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 89.07 | 37.97 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.16 | $0.55 |
| 52 Week High | $1.50 | $2.65 |
Technical Indicators
Market Signals| Indicator | TOVX | APRE |
|---|---|---|
| Relative Strength Index (RSI) | 41.68 | 41.59 |
| Support Level | $0.17 | $0.55 |
| Resistance Level | $0.26 | $0.98 |
| Average True Range (ATR) | 0.01 | 0.08 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 3.91 | 2.44 |
Price Performance
Historical ComparisonAbout TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.
About APRE Aprea Therapeutics Inc.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.